Advanced Solid Tumor Clinical Trials in Santa Monica, California

8 studies are recruiting for advanced solid tumor in Santa Monica, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors

   A Phase 1 First-in-Human study of YL217 in Patients with Advanced Solid Tumors

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCLA Hematology/Oncology - Santa Monica, Santa Monica, California

   Locations

   21 in total

   Run by

   MediLink Therapeutics (Suzhou) Co., Ltd.

   See if you can join NCT06859762 on ClinicalTrials.gov

2. A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

   The main purpose of this study is to find out whether the study drug, LY4050784, is safe, tolerable and effective in participants alone or in combination with other anticancer agents. In addition, with locally advanced or metastatic solid tumors with a BRG1 (Brahma-related gene 1, also known as SMA…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCLA, Santa Monica, California

   Locations

   33 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06561685 on ClinicalTrials.gov

3. SW-682 in Advanced Solid Tumors

   This is a first-in-human (FIH), Phase 1a/1b open-label, multicenter, dose escalation and dose expansion study of SW-682 in adult participants with metastatic or unresectable advanced solid tumors with or without Hippo pathway alterations that are refractory to, or have progressed, during or after a…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCLA Hematology-Oncology - Santa Monica, Santa Monica, California

   Locations

   8 in total

   Run by

   SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

   See if you can join NCT06251310 on ClinicalTrials.gov

4. Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

   This is a phase 1/2, multicenter, open-label study. The phase 1 portion is a dose escalation and expansion study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors. The phase 2 portion is a randomized study of STK-012 in combination with standard of…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCLA Hematology/Oncology - Santa Monica, Santa Monica, California

   Locations

   47 in total

   Run by

   Synthekine

   See if you can join NCT05098132 on ClinicalTrials.gov

5. Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

   This is an open-label, multi-center, phase 1b study designed to determine a tolerable dose of CX-5461 administered by IV infusion on Day 1 and Day 8 of a 28-day cycle in patients with selected solid tumours and associated mutations for future Phase II trials. The safety and tolerability of CX-5461,…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California, Los Angeles, Santa Monica, California

   Locations

   8 in total

   Run by

   Senhwa Biosciences, Inc.

   See if you can join NCT04890613 on ClinicalTrials.gov

6. A Study of DB-1310 in Advanced/Metastatic Solid Tumors

   This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1310 in subjects with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCLA Hematology/Oncology - Santa Monica, Santa Monica, California

   Locations

   24 in total

   Run by

   DualityBio Inc.

   See if you can join NCT05785741 on ClinicalTrials.gov

7. A Beta-only IL-2 ImmunoTherapY Study

   This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Providence Saint John's Health Center, Santa Monica, California

   Locations

   27 in total

   Run by

   Medicenna Therapeutics, Inc.

   See if you can join NCT05086692 on ClinicalTrials.gov

8. This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid Tumors

   This is a first-in-human Phase 1, single-arm, open-label, multicenter, multiple-dose, dose-escalation and dose-expansion study of ABL503 to evaluate the safety, tolerability, MTD and/or RP2D, PK, immunogenicity, preliminary antitumor activity, and the PD effect of ABL503 in subjects with any progre…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCLA, Santa Monica, California

   Locations

   8 in total

   Run by

   ABL Bio, Inc.

   See if you can join NCT04762641 on ClinicalTrials.gov